HOYA Vision Care Presents Results of First Six-Year MiYOSMART Spectacle Lens Follow-up Clinical Study at EAOO Conference

DUBLIN – 16 May 2022 – HOYA Vision Care, a leader in optical technology innovation, presented the results of a six-year follow-up clinical study on its award winning MiYOSMART spectacle lens with Defocus Incorporated Multiple Segments (D.I.M.S.) Technology at the European Academy of Optometry and Optics (EAOO) 2022 conference in Dublin, Ireland on 16 May. The findings, of the longest study on a myopia management spectacle lens, were shared by Professor Carly Lam from the Centre for Myopia Research at The Hong Kong Polytechnic University who conducted the research.  Birte Graff of the Internationale Innovative Ophthalmochirurgie (I.I.O.) in Germany also took part in the session discussing Childhood Myopia: Diagnosis and Therapy.


The results of the six-year clinical study conducted on 90 children in Asia looked at the progression of myopia in children who wore the HOYA Vision Care’s MiYOSMART spectacle lens. The results enhanced a previous three-year follow-up study1, a continuation of a two-year randomized controlled trial (RCT)2, which was published in the British Journal of Ophthalmology, demonstrating strong evidence of the lenses’ effectiveness in slowing down the progression of myopia in children ages 8-13.  The findings of the six-year, long-term follow-up clinical study proved the MiYOSMART spectacle lens myopia control effect is sustained over time for children wearing the lens. It also confirmed that patients who stop wearing the MiYOSMART spectacle lens show no rebound effect when compared to the initial myopia rates of progression during the two-year randomized controlled trial or with the general population.3


“We are proud to share our six-year clinical study on the MiYOSMART lens, the longest study conducted on a myopia management spectacle lens ever with this European audience of eye care professionals. The study importantly shows that the myopia control effect is sustainable over time which is very exciting news,” said Natalia Vlasak, ophthalmologist, Global head of Medical and Scientific Affairs at HOYA Vision Care.


“This study also answered another key question from eye care professionals which was about the rebound effect of the lens - we are very pleased that this clinical study proves that there is no rebound effect if lens use is stopped.” “HOYA Vision Care is dedicated to being a leader in developing a safe, effective way to manage the growing problem of myopia in children,” she added.


Launched in 2018, the MiYOSMART spectacle lens was developed in cooperation with The Hong Kong Polytechnic University to address myopia, or near sightedness which is a growing global health concern with industry experts predicting nearly 50% of the world’s population to be impacted by 2050.4 The lens uses D.I.M.S. Technology that provides children with sharp vision, can be placed in any children’s eyeglass frame and appears as a standard spectacle lens.  Since 2018, one million patients in more than 30 countries have benefited from wearing the MiYOSMART lens.5


The MIYOSMART spectacle lens currently available in more than 30 countries including 14 in Europe and the UK, continues to be rolled out globally. Since 2018, one million patients in more than 30 countries have benefited from wearing the MiYOSMART spectacle lens.4


1 Lam CS, Tang WC, Lee PH, et al. Myopia control effect of defocus incorporated multiple segments (DIMS) spectacle lens in Chinese children: results of a 3-year follow-up study. British Journal of Ophthalmology Published Online First: 17 March 2021. doi: 10.1136/bjophthalmol-2020-317664

2Lam CSY, Tang WC, Zhang A, Tse D, To CH. Myopia control in children wearing DIMS spectacle lens: 6 years results. The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting, May 1-4, Denver, US.

3 Lam CSY, Tang WC, Tse DY, Lee RPK, Chun RKM, Hasegawa K, Qi H, Hatanaka T, To CH. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomized clinical trial. British Journal of Ophthalmology. Published Online First: 29 May 2019. doi: 10.1136/bjophthalmol-2018-313739

4Holden B.A., Fricke T.R., Wilson D.A., Jong M., Naidoo K.S., Sankaridurg P., Wong T.Y., Naduvilath T.J., Resniko_ S. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. American Academy of Ophthalmology. 05/2016, vol.123, no. 5, p.1036–1042.

5Based on number of lenses sold per HOYA sales data on file as of February 2022. Individual wearer results may vary.



PRODUCT DISCLAIMER – MiYOSMART has not been approved for myopia management in all countries, including the U.S., and is not currently available for sale in all countries, including the U.S.


About HOYA Vision Care

As a global leader in optical technology, HOYA Vision Care is dedicated to providing innovative vision care solutions for every stage of a patient’s life. A steadfast partner to Eye Care Professionals around the world, it stands at the forefront of optical excellence. With a global presence, consisting of 43 laboratories and a growing team of 20,000 employees, HOYA Vision Care delivers innovative lenses and other vision care solutions to millions of people in 110 countries.

About HOYA

For further information contact: